Beyond BYON 深 滬
已收盤 08-28 16:00:00 美东时间
9.44
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 9.44
- 總市值 5.42亿
- 52周最高 12.24
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.54
- 委 比 0.00%
- 總股本 5740.60万
- 歷史最高 37.10
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3.54
- 每 手 1
- 風險率 1.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Senate Democrats press Fiserv for details on ex-CEO Frank Bisignano's role
U.S. Senate Democrats Ron Wyden and Elizabeth Warren are demanding answers from Fiserv (FI) about former CEO Frank Bisignano's role in the payment technology company's recent slump and its discredited...
今天 02:13
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on therapy for major depressive disorder.
今天 01:57
TELUS declares CAD 0.4184 dividend
TELUS (TU) declares CAD 0.4184/share quarterly dividend. Payable Jan. 2; for shareholders of record Dec. 11; ex-div Dec. 11. See TU Dividend Scorecard, Yield Chart, & Dividend Growth. More on TELUS Co...
11-07 21:22
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics于2025年11月4日向6名新员工授予了非合格股票期权和限制性股票单位（RSUs），总计79,050股普通股期权和39,915股RSUs，行权价为每股24.35美元，基于2025年11月4日的收盘价。期权和RSUs均需在4年内按特定条件归属，归属条件包括员工持续服务关系。Vera Therapeutics是一家专注于开发严重免疫疾病治疗的晚期临床生物技术公司，其主要候选药物为Atacicept，一种可通过皮下注射的融合蛋白，旨在阻断B细胞激活因子（BAFF）和增殖诱生配体（APRIL），从而减少自身免疫性疾病中的自身抗体产生。此外，公司还开发了VT-109和MAU868，分别针对BAFF/APRIL和BK病毒的mAb。投资者可联系Joyce Allaire，媒体可联系Debra Charlesworth获取更多信息。
11-07 21:05
12 Top Press Releases from October
Including a shipment of rare earth minerals, Evernorth's plans to go public, LeBron James's announcement with Hennessy and a recap of top Halloween news. NEW YORK, Nov. 7, 2025 /PRNewswire/ ...
11-07 19:02
“Trump’s Pharmacy” Cutting Weight-Loss Drug Prices — What This Means for Novo and Lilly
TradingKey - Following agreements with Pfizer and AstraZeneca, the so-called “twin giants” of weight-loss drugs — Novo Nordisk and Eli Lilly — have now also reached pricing deals with the Trump administration. This marks the latest move in Trump’s broader push to cut U.S. drug prices by up to 90%
11-07 12:59
ARC Resources GAAP EPS of C$0.68
ARC Resources press release (ARX:CA): Q3 GAAP EPS of C$0.68. More on ARC Resources Arc Resources: Look Beyond 2028 At This Undervalued Cannibal ARC Resources announces new share buyback program of up ...
11-07 12:29
Western Union Unveils ‘Beyond’ Strategy at Investor Day
Western Union ( ($WU) ) has shared an update. On November 6, 2025, Western Unio...
11-06 21:29
Jacobs Expands Role in Jackson, Mississippi with New Wastewater Operations Contract
Nine-year agreement will modernize wastewater systems and build operational resilience DALLAS, Nov. 6, 2025 /PRNewswire/ -- Jacobs (NYSE: J) was awarded a nine-year contract by JXN Water to ...
11-06 20:45
The Analyst Verdict: Coherent In The Eyes Of 11 Experts
Providing a diverse range of perspectives from bullish to bearish, 11 analysts ...
11-06 19:44
